吲哚美辛与双氯芬酸预防内镜逆行胰胆管造影术后胰腺炎:前瞻性对照试验的系统评价与荟萃分析
该系统评价与荟萃分析检索截至2016年6月30日的数据库,纳入17项前瞻性对照试验共4741例患者,评估双氯芬酸或吲哚美辛预防内镜逆行胰胆管造影术后胰腺炎(PEP)的疗效。结果显示双氯芬酸或吲哚美辛显著降低PEP风险比至0.60(95%CI 0.46-0.78;P=0.0001),需治疗人数为20,中重度PEP风险比降低为0.64(95%CI 0.43-0.97;P=0.0339);直肠给药非常有效(P=0.0005),需治疗人数为19,非直肠给药效果不显著(P=0.1507)。作者结论认为直肠给予双氯芬酸或吲哚美辛廉价安全,推荐用于所有无肾衰竭的ERCP患者。
要点
- 双氯芬酸或吲哚美辛显著降低PEP风险比至0.60(95%CI 0.46-0.78;P=0.0001),需治疗人数为20。
- 中重度PEP风险比降低为0.64(95%CI 0.43-0.97;P=0.0339)。
- 直肠给药非常有效(P=0.0005),需治疗人数为19;非直肠给药效果不显著(P=0.1507)。
核心结论
- 直肠给予双氯芬酸或吲哚美辛在ERCP前或紧接ERCP后使用廉价且安全,推荐用于所有无肾衰竭的ERCP患者。
研究设计与样本
- 系统检索PubMed、Scopus、Web of Science和Cochrane数据库,纳入从建库至2016年6月30日发表、以安慰剂或不治疗为对照、研究双氯芬酸或吲哚美辛预防成人ERCP术后PEP疗效的全部前瞻性对照试验全文。
- 荟萃分析纳入17项试验共4741例患者。
主要发现
- 双氯芬酸或吲哚美辛显著降低PEP风险比至0.60(95%CI 0.46-0.78;P=0.0001),需治疗人数为20。
- 中重度PEP风险比降低为0.64(95%CI 0.43-0.97;P=0.0339)。
- 吲哚美辛与双氯芬酸疗效相似(P=0.98)。
- 吲哚美辛或双氯芬酸疗效不因给药时机(P=0.99)或PEP平均风险与高风险患者(P=0.6923)而异。
- 非直肠给予吲哚美辛或双氯芬酸效果不显著(P=0.1507),但直肠途径非常有效(P=0.0005),需治疗人数为19。
关键数值与推荐
- 双氯芬酸或吲哚美辛使PEP风险比降至0.60(95%CI 0.46-0.78;P=0.0001),需治疗人数为20。
- 中重度PEP风险比降低为0.64(95%CI 0.43-0.97;P=0.0339)。
- 直肠给药需治疗人数为19(P=0.0005);非直肠给药效果不显著(P=0.1507)。
临床怎么用
- 作者推荐在ERCP前或紧接ERCP后直肠给予双氯芬酸或吲哚美辛,用于所有无肾衰竭的ERCP患者。
- 有肾衰竭的患者避免使用吲哚美辛或双氯芬酸。
- 未检测到明显不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Diclofenac and indomethacin are the most studied drugs for preventing post-ERCP pancreatitis (PEP). However, there are no prospective, randomized multicenter trials with a sufficient number of patients for correct evaluation of their efficacy. Our aim was to evaluate all prospective trials published in full text that studied the efficacy of diclofenac or indomethacin and were controlled with placebo or non-treatment for the prevention of PEP in adult patients undergoing ERCP. METHODS: Systematic search of databases (PubMed, Scopus, Web of Science, Cochrane) for relevant studies published from inception to 30 June 2016. RESULTS: Our meta-analysis of 4741 patients from 17 trials showed that diclofenac or indomethacin significantly decreased the risk ratio (RR) of PEP to 0.60 (95% confidence interval [CI], 0.46-0.78; P = .0001), number needed to treat (NNT) was 20, and the reduction of RR of moderate to severe PEP was 0.64 (95% CI, 0.43-0.97; P = .0339). The efficacy of indomethacin compared with diclofenac was similar (P = .98). The efficacy of indomethacin or diclofenac did not differ according to timing (P = .99) or between patients with average-risk and high-risk for PEP (P = .6923). The effect of non-rectal administration of indomethacin or diclofenac was not significant (P = .1507), but the rectal route was very effective (P = .0005) with an NNT of 19. The administration of indomethacin or diclofenac was avoided in patients with renal failure. Substantial adverse events were not detected. CONCLUSIONS: The use of rectally administered diclofenac or indomethacin before or closely after ERCP is inexpensive and safe and is recommended in every patient (without renal failure) undergoing ERCP. (Registration number: CRD42016042726, http://www.crd.york.ac.uk/prospero/.).
引用
- Patai Á, Solymosi N, Mohácsi L, et al. Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. Gastrointest Endosc. 2017. PMID: 28167118. doi:10.1016/j.gie.2017.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。